KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Thermo Fisher Scientific (TMO) Cash & Equivalents (2016 - 2026)

Thermo Fisher Scientific filings provide 18 years of Cash & Equivalents readings, the most recent being $3.3 billion for Q1 2026.

  • On a quarterly basis, Cash & Equivalents fell 21.29% to $3.3 billion in Q1 2026 year-over-year; TTM through Mar 2026 was $3.3 billion, a 21.29% decrease, with the full-year FY2025 number at $9.9 billion, up 145.75% from a year prior.
  • Cash & Equivalents hit $3.3 billion in Q1 2026 for Thermo Fisher Scientific, down from $9.9 billion in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $9.9 billion in Q4 2025 to a low of $1.9 billion in Q3 2022.
  • Median Cash & Equivalents over the past 5 years was $4.1 billion (2025), compared with a mean of $4.8 billion.
  • Biggest five-year swings in Cash & Equivalents: tumbled 75.73% in 2022 and later soared 145.75% in 2025.
  • Thermo Fisher Scientific's Cash & Equivalents stood at $8.5 billion in 2022, then fell by 5.24% to $8.1 billion in 2023, then plummeted by 50.37% to $4.0 billion in 2024, then surged by 145.75% to $9.9 billion in 2025, then crashed by 66.97% to $3.3 billion in 2026.
  • The last three reported values for Cash & Equivalents were $3.3 billion (Q1 2026), $9.9 billion (Q4 2025), and $2.0 billion (Q3 2025) per Business Quant data.